Escherichia coli strain Nissle 1917 ameliorates experimental colitis by modulating intestinal permeability, inflammatory response and clinical signs in a faecal transplantation model.

Escherichia coli strain Nissle 1917 ameliorates experimental colitis by modulating intestinal permeability, inflammatory response and clinical signs in a faecal transplantation model. J Med Microbiol. 2016 Jan 12; Authors: Souza ÉL, Elian SD, Paula LM, Garcia CC, Vieira AT, Teixeira MM, Arantes RM, Nicoli JR, Martins FS Abstract Inflammatory bowel diseases (IBD) are a group of inflammatory conditions of the gut that includes ulcerative colitis and Crohn's disease. Probiotics are live microorganisms that may be used as adjuvant therapy for patients with IBD. The aim of this study was to evaluate the effect of prophylactic ingestion of Escherichia coli Nissle 1917 (EcN) in a murine model of colitis. For induction of colitis, mice were given a 3.5% Dextran Sodium Sulphate (DSS) solution for 7 days in drinking water. EcN administration to mice subjected to DSS-induced colitis resulted in significant reduction of clinical and histopathological signs of disease and preservation of intestinal permeability. We observed reduced inflammation, as assessed by reduced levels of neutrophils and eosinophils, chemokines and cytokines. We observed an increase in number of regulatory T cells in Peyer´s patches. Germ free mice received faecal content from control or EcN-treated mice and were then subjected to DSS-induced colitis. We observed protection from colitis in animals that were colonized with faecal content from EcN-treated mice. These result...
Source: Journal of Medical Microbiology - Category: Microbiology Authors: Tags: J Med Microbiol Source Type: research